Compound Evidence File
#EC-2026-0044
MGF
Filed under Peptides. The bureau holds 90 laboratory returns for this compound from 36 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
36 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| CellupepCASE #VI-2026-0888 | X | 1 | 10.0 | 10.0 | 10.0 | 14 Jan 2025 | 14 Jan 2025 |
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 5 | 9.9 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| HomopeptideCASE #VI-2026-0760 | A | 4 | 9.9 | 9.9 | 10.0 | 24 May 2026 | 24 May 2026 |
| Glamgurcraft Innovations Foreign TradeCASE #VI-2026-0348 | X | 1 | 9.5 | 9.5 | 9.5 | 9 Jun 2025 | 9 Jun 2025 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 8 | 8.8 | 7.1 | 10.0 | 24 May 2026 | 24 May 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 8 | 8.4 | 7.1 | 10.0 | 24 May 2026 | 24 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 7 | 8.4 | 7.3 | 9.6 | 24 May 2026 | 24 May 2026 |
| Peptide CraftersCASE #VI-2026-0994 | X | 1 | 8.3 | 8.3 | 8.3 | 20 Jun 2025 | 20 Jun 2025 |
| HealthTide BiotechCASE #VI-2026-0955 | X | 1 | 8.3 | 8.3 | 8.3 | 3 Jul 2025 | 3 Jul 2025 |
| Xianhong Tong XHT PeptidesCASE #VI-2026-0997 | X | 1 | 8.1 | 8.1 | 8.1 | 3 Jun 2025 | 3 Jun 2025 |
| Dragon PharmaCASE #VI-2026-0519 | X | 1 | 7.8 | 7.8 | 7.8 | 11 Jun 2025 | 11 Jun 2025 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 7 | 7.7 | 6.5 | 10.0 | 21 May 2026 | 21 May 2026 |
| Hebei Rimao TechnologyCASE #VI-2026-0529 | X | 2 | 7.7 | 5.4 | 10.0 | 14 Jan 2025 | 21 May 2026 |
| Bio PepzCASE #VI-2026-0436 | X | 1 | 7.7 | 7.7 | 7.7 | 17 Dec 2024 | 17 Dec 2024 |
| Shanghai BaojuCASE #VI-2026-0233 | X | 1 | 7.7 | 7.7 | 7.7 | 21 May 2025 | 21 May 2025 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 7 | 7.5 | 6.0 | 8.6 | 23 May 2026 | 23 May 2026 |
| Diju Peptides Wellness and CoCASE #VI-2026-0724 | X | 1 | 7.4 | 7.4 | 7.4 | 25 Apr 2025 | 25 Apr 2025 |
| AKS ChemCASE #VI-2026-0313 | X | 1 | 7.4 | 7.4 | 7.4 | 13 Jun 2025 | 13 Jun 2025 |
| TCICASE #VI-2026-0650 | X | 1 | 7.1 | 7.1 | 7.1 | 16 Mar 2025 | 16 Mar 2025 |
| Zenith Jove Peptide ZJCASE #VI-2026-0570 | X | 1 | 7.1 | 7.1 | 7.1 | 27 Feb 2025 | 27 Feb 2025 |
| Evolve BioPepCASE #VI-2026-0755 | X | 1 | 6.9 | 6.9 | 6.9 | 14 Jan 2025 | 14 Jan 2025 |
| Welon Peptide SolutionsCASE #VI-2026-0478 | X | 1 | 6.8 | 6.8 | 6.8 | 6 May 2025 | 6 May 2025 |
| Planet PeptideCASE #VI-2026-0092 | X | 5 | 6.7 | 4.4 | 9.4 | 28 Mar 2025 | 23 May 2026 |
| LiliPeptideCASE #VI-2026-0695 | X | 4 | 6.6 | 6.3 | 6.9 | 14 Jan 2025 | 17 May 2026 |
| Xian Yihang TechnologyCASE #VI-2026-0656 | X | 4 | 6.5 | 6.0 | 7.3 | 7 May 2025 | 24 May 2026 |
| NexaphCASE #VI-2026-0944 | X | 4 | 6.4 | 4.9 | 7.5 | 28 Mar 2025 | 25 May 2026 |
| Peptide HavenCASE #VI-2026-0898 | X | 1 | 6.4 | 6.4 | 6.4 | 28 Mar 2025 | 28 Mar 2025 |
| Hangzhou Mandy BiotechnologyCASE #VI-2026-0695 | X | 1 | 6.2 | 6.2 | 6.2 | 8 Jul 2025 | 8 Jul 2025 |
| Hangzhou Youngpeptide Biotechnology HYBCASE #VI-2026-0347 | X | 1 | 5.1 | 5.1 | 5.1 | 9 Jun 2025 | 9 Jun 2025 |
| Heman Peptide HMCASE #VI-2026-0089 | X | 1 | 5.0 | 5.0 | 5.0 | 11 Jun 2025 | 11 Jun 2025 |
| Guangzhou Lengiuanhuang CosmeticsCASE #VI-2026-0228 | X | 1 | 4.5 | 4.5 | 4.5 | 25 Apr 2025 | 25 Apr 2025 |
| LN PeptidesCASE #VI-2026-0781 | X | 2 | 4.4 | 1.2 | 7.6 | 28 Mar 2025 | 20 May 2026 |
| Richards Biotech Simply RichardsCASE #VI-2026-0307 | X | 1 | 4.3 | 4.3 | 4.3 | 24 Apr 2025 | 24 Apr 2025 |
| Peptide GurusCASE #VI-2026-0854 | X | 2 | 3.5 | 3.3 | 3.7 | 27 Feb 2025 | 17 May 2026 |
| PeptiLab ResearchCASE #VI-2026-0267 | X | 1 | 3.4 | 3.4 | 3.4 | 21 May 2025 | 21 May 2025 |
| SubQ SocietyCASE #VI-2026-0716 | X | 1 | 0.7 | 0.7 | 0.7 | 9 Jun 2025 | 9 Jun 2025 |
Open any subject to view the batch-level evidence for MGF alone.